World Antimalarial Resistance Network (WARN) III: Molecular markers for drug resistant malaria
-
* Corresponding author: Carol H Sibley sibley@u.washington.edu
Malaria Journal 2007, 6:121 doi:10.1186/1475-2875-6-121
Accesses
- Last 30 days: 238 accesses
- Last year: 2216 accesses
- All time: 10165 accesses
Cited by
BioMed Central: 9 citations
|
Methodology
Edwin Kamau, Saba Alemayehu, Karla C Feghali, LaDonna S Tolbert, Bernard Ogutu, Christian F Ockenhouse Malaria Journal 2012, 11:23 (20 January 2012) Paper reporting the development of a TaqMan Real Time PCR assay for the detection of SNPs associated with anti-malarial resistance. This assay has promise as a convenient and efficient way to examine patient samples in resource-constrained settings.
|
|
Methodology
Céline Barnadas, David Kent, Lincoln Timinao, Jonah Iga, Laurie R Gray, Peter Siba, Ivo Mueller, Peter J Thomas, Peter A Zimmerman Malaria Journal 2011, 10:282 (24 September 2011) Monitoring P. vivax resistance to anti-malarial drugs in vivo and in vitro remaind challenging, but some molecular markers of resistance can be used in surveillance studies. A new high-throughput assay relevant markers of drug resistance was developed and assessed on Papua New Guinea patient isolates.
|
|
Research
Reem A Mubjer, Ahmed A Adeel, Michael L Chance, Amir A Hassan Malaria Journal 2011, 10:245 (21 August 2011) Baseline information on the characteristics and implications of anti-malarial drug resistance markers in Yemen.
|
|
Research
Jutta Marfurt, Thomas A Smith, Ian M Hastings, Ivo Müller, Albert Sie, Olive Oa, Moses Baisor, John C Reeder, Hans-Peter Beck, Blaise Genton Malaria Journal 2010, 9:8 (7 January 2010) Interesting paper aiming at investigating the role and applicability of the molecular drug resistance profiles in community samples in Papua New Guinea.
|
|
Methodology
Nicolas Steenkeste, Marie-Agnès Dillies, Nimol Khim, Odile Sismeiro, Sophy Chy, Pharath Lim, Andreas Crameri, Christiane Bouchier, Odile Mercereau-Puijalon, Hans-Peter Beck, Mallika Imwong, Arjen M Dondorp, Duong Socheat, Christophe Rogier, Jean-Yves Coppée, Frédéric Ariey Malaria Journal 2009, 8:229 (15 October 2009) This paper describes a new microarray system to detect mutations associated with resistance to anti-malarials. Such microarrays could be employed to monitor P. falciparum drug resistance markers with greater cost effectiveness and the possibility for high throughput analysis.
|
|
Research
Elizabeth N Allen, Francesca Little, Tunisio Camba, Yasmin Cassam, Jaishree Raman, Andrew Boulle, Karen I Barnes Malaria Journal 2009, 8:141 (26 June 2009) This clinical trial produced clear evidence that ACT substantially reduced treatment failure, recrudescence and gametocyte carriage, which had not been reported for Mozambique
|
|
Research
Stéphane Picot, Piero Olliaro, Frédérique de Monbrison, Anne-Lise Bienvenu, Ric N Price, Pascal Ringwald Malaria Journal 2009, 8:89 (4 May 2009) This meta-analysis brings together available data on association between various genetic polymorphisms in Plasmodium falciparum and clinical treatment failure of anti-malarial drugs, and is a valuable summary of the published literature on this topic.
|
|
Methodology
Jonathan J Juliano, Milijaona Randrianarivelojosia, Benjamin Ramarosandratana, Frédéric Ariey, Victor Mwapasa, Steven R Meshnick Malaria Journal 2009, 8:47 (16 March 2009) A study that addresses the important methodological issue of how to detect minor sub-populations of P. falciparum parasites in infected hosts harbouring multiple genotypes.
|
|
Review
World Antimalarial Resistance Network (WARN) IV: Clinical pharmacology Karen I Barnes, Niklas Lindegardh, Olumide Ogundahunsi, Piero Olliaro, Christopher V Plowe, Milijaona Randrianarivelojosia, Grace O Gbotosho, William M Watkins, Carol H Sibley, Nicholas J White Malaria Journal 2007, 6:122 (6 September 2007) This article is part of a collection on The world antimalarial... The determinants of treatment response are multi-factorial, but reaching adequate blood concentrations is pivotal to cure. Pharmacokinetic data can inform on optimal dosing, but only small number of patients have been studied, with even less conducted in the most vulnerable populations. A better understanding of the pharmacokinetic properties of antimalarials and a more clear definition of what constitutes “therapeutic drug levels” would allow more precise use of the term “antimalarial resistance”, as it would indicate when treatment failure is not caused by intrinsic parasite resistance but is the result of inadequate drug levels.
|